Theriva Biologics Inc TOVX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 1993-02-12 |
| Shares Out. | 45,890,000 |
| Website | therivabio.com/ ↗ |
| Phone | 17343327800 |
| Employees | 16 |
| Revenue | $300,000 |
| Gross Profit | $300,000 |
| Net Income | -$2.0M |
| Free Cash Flow | -$14.4M |
| Total Assets | $38.2M |
| Total Liabilities | $22.8M |
| Equity | $15.4M |
About Theriva Biologics Inc
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Theriva Biologics Inc is a publicly traded company under the ticker symbol TOVX on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)